louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03314051: Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA
Official title: Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nasopharyngeal Carcinoma
EBV Related Carcinoma
Keywords: Nasopharyngeal Carcinoma
plasma EBV DNA
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2017-10-19
Enrollment: 366
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Tissue proven stage III NPC patients and received curative treatment in our institute. Pre-treatment and post-radiotherapy plasma EBV DNA will be obtained.

Brief summary: No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.

Detailed description: The stage III NPC patients were the majority group of the patient population of NPC. But most clinical trials focused on the treatment of American Joint Committee on Cancer (AJCC) 7th edition stage IVA/IVB treatment for high risk of recurrence or metastasis. No previous study reported the treatment outcome of stage III NPC patients. The investigators tried to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma EBV DNA assay for future therapy improvement.

Eligibility criteria: Inclusion Criteria:

* Biopsy-proven stage III nasopharyngeal carcinoma (NPC)
* Finished curative chemoradiotherapy
* Have Pre-treatment and post-radiotherapy plasma EBV DNA

Exclusion Criteria:

* No tissue proven NPC
* Not finished curative treatment
* No Pre-treatment and post- radiotherapy plasma EBV DNA

Primary outcomes:
measure: Overall survival (OS)
timeFrame: 5 year
Secondary outcomes:
measure: Progression-free survival (PFS)
timeFrame: 5 year
measure: Distant metastasis failure-free survival (DMFFS)
timeFrame: 5 year
measure: Locoregional failure-free survival (LRFFS)
timeFrame: 5 year
Other outcomes:
Locations:
Study officials:
affiliation: Department of Radiation Oncology, Taichung Veterans General Hospital
name: Jin-Ching Lin, MD.PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06777251: Changing the Future of Intestinal Failure in Intestinal Chronic Inflammation (INT-FAIL)
Official title: Changing the Future of Intestinal Failure in Intestinal Chronic Inflammation: Towards Innovative Predictive Factors and Therapeutic Targets.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Intestinal Failure
Inflammatory Bowel Diseases
Crohn Disease
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
First posted: 2025-01-15
Enrollment: 254
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: DIAGNOSTIC

Brief summary: This is an interventional, prospective, no profit study that will be performed at CEMAD, from FONDAZIONE POLICLINICO GEMELLI IRCCS, Rome (UO1) and U.O.C. Internal Medicine and Gastroenterology from Ospedale Brotzu di Cagliari (UO4). Adult patients with Crohn Disease (CD) and chronic intestinal insufficiency (CF) and adult patients with CD at high and low risk of CF.

Detailed description: The study involves an initial evaluation in which faecal samples will be collected, a blood sample will be taken and an ileocolonoscopy with biopsy (additional biopsy collection at the same time as clinical practice biopsy for study-specific analysis) will be performed.

Patients will then be re-evaluated nine months after the initial evaluation. In particular, faecal, blood and additional biopsy samples will be collected at the same time as the clinical practice biopsy and any changes in treatment will be recorded.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years-old and ≤ 75 years old
* Capable of expressing informed consent;
* An established diagnosis of Crohn's disease;
* Antibiotics treatment free for at least 15 days.

Exclusion Criteria:

* Age \< 18 years-old and \> 75 years old;
* Not capable of expressing informed consent;
* Pregnant or breastfeeding patients;
* Comorbidities including: cancer pathology present or under active treatment; coagulopathies; chronic hepatopathy, heart failure, renal failure, respiratory failure.

Primary outcomes:
measure: Predictive Factors for FH in Crohn's Disease Using Gut Microbiota Composition
timeFrame: 24 month
measure: Predictive Factors for FH in Crohn's Disease Using Metabolome Analysis
timeFrame: 24 month
measure: Predictive Factors for FH in Crohn's Disease Using Immunological Signature Characterization
timeFrame: 24 month
Secondary outcomes:
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Fondazione Policlinico Universitario A. Gemelli IRCCS
Study officials:
affiliation: Fondazione Policlinico A. Gemelli IRCCS, Rome
name: Alfredo Papa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06674551: Suprascapular and Axillary Versus Interscalene Blocks Regarding Phrenic Affection in Shoulder Surgeries
Official title: Comparative Study Between Combined Suprascapular and Axillary Nerve Blocks Versus Interscalene Nerve Block Regarding Phrenic Nerve Affection Assessed by Ultrasound Guided Diaphragmatic Excursion in Shoulder Arthroscopy Surgeries
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Interscalene Nerve Block
Suprascapular Nerve
Shoulder Surgery
Keywords: interscalene nerve block
axillary nerve block
shoulder surgery
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-11-05
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is aims to compare between combined suprascapular and axillary nerve blocks versus interscalene nerve block regarding phrenic nerve affection assessed by ultrasound guided diaphragmatic excursion in shoulder arthroscopy surgeries.

Detailed description: Interscalene approach of brachial plexus nerve block is recognized as the gold standard technique for postoperative pain control after shoulder arthroscopy surgeries . However, it is associated with major adverse effects and possibly critical complications including phrenic nerve affection. Combined suprascapular and axillary nerve blocks are considered to be a safe and effective alternative to interscalene nerve block for shoulder surgery. Futher studies had been done regarding postoperative analgesia after shoulder arthroscopy surgeries using intersalene nerve block versus suprascapular and axillary nerve blocks.

In this study, we will Compare between combined suprascapular and axillary nerve blocks vs interscalene nerve block regarding objective phrenic nerve affection known as a serious complication of interscalene nerve block.

Eligibility criteria: Inclusion Criteria:

* Patients aged between 18 - 60 years old.
* Both sexes.
* ASA physical status classes I - II.
* Body mass index: 18-35 kg/ m2.

Exclusion Criteria:

* Infection at site of injection.
* Psychiatric illness.
* Central Nervous System Diseases like (epilepsy, stroke ...etc.) or neurological disease affecting patient's upper limb.
* Dependence on opiates and psycho-dynamic medications.
* Moderate to severe pulmonary disease.
* Coagulopathy and bleeding disorders.
* Allergies to drug used (Bupivacaine 0.5%).
* Previous surgery at site of injection and history of radiotherapy.

Primary outcomes:
measure: incidence of hemidiaphragmatic paralysis measured by ultrasound.
timeFrame: measurement will be taken 8 hours after the performance of the block for fourth and last time.
Secondary outcomes:
measure: postoperative pain using NRS
timeFrame: 24 hours postoperative
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01785654: Hemodynamic and Biological Evaluations During Reventilation Collapse in ICU
Official title: Hemodynamic and Biological Evaluations During Reventilation Collapse in ICU
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Arterial Line
Consent of Patients
Adult Patients
Tracheal Intubation in ICU
Keywords: Reventilation collapse
Rate of reventilation collapse
Risk factor of reventilation collapse
Hemodynamic profile of reventilation collapse
Biologic approach of reventilation collapse
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2013-02-07
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Defined population

Brief summary: Prospective, observational clinical multicentric study in ICU; during the period surrounding the orotracheal intubation.

Detailed description: Main objective: to describe the characteristics of reventilation collapse: collapse rate, duration and treatment implemented

Secondary objectives:

* identify risk factors of reventilation collapse
* compare mortality, hemodynamic, respiratory, infectious and biological data between collapse group and no reventilation collapse group.

Eligibility criteria: Inclusion Criteria:

* Arterial line
* Consent of patients
* Adult patients
* Tracheal intubation in ICU

Exclusion Criteria:

* tracheal intubation for cardiac arrest
* pregnant woman
* major protected

Primary outcomes:
measure: Reventilation collapse
timeFrame: at day 1 (at least thirty minutes despite 500 or 1000ml of fluid resuscitation)
Secondary outcomes:
measure: reventilation collapse
timeFrame: in the last 72 hours
measure: Duration of mechanical ventilation
timeFrame: at day 1
measure: mortality
timeFrame: at day 28
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Sebastien PERBET
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05057754: Sonographic Measurement of Intraneural Blood Flow in the Median Nerve
Official title: Enhancing Sonographic Measurement of Intraneural Blood Flow in the Median Nerve
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carpal Tunnel Syndrome
Median Nerve Injury
Keywords: intraneural blood flow
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2021-09-27
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Carpal tunnel syndrome (CTS) is the most common nerve compression disease and the most expensive upper-extremity work-related musculoskeletal disorder, affecting approximately 10 million people in the US. To understand the clear etiology and mechanism of carpal tunnel syndrome, the measurement of median nerve intraneural blood flow needs to be further scrutinized as the common fluctuating physiological conditions and functional hand activities might contribute to the fluctuation of the measurement and serve as measurement error. This study aims to examine how intraneural blood flow within the median nerve is affected by physiological factors (i.e., body temperature and blood pressure) and functional hand activities (i.e., typing, using a mouse, and cooking).


Eligibility criteria: Inclusion Criteria:

* Aged 18 to 65
* English-speaking
* Ability to endure a moderate-intensity physical activity
* Ability to type without looking at the keyboard

Exclusion Criteria:

* Pain, tingling, or numbness in the hand or wrist region within the past week
* History of corticoid injection in the upper extremity
* History of surgery in the wrist region
* Carpal tunnel syndrome
* Amyotrophic lateral sclerosis
* Diabetes
* Hypothyroidism
* Pregnant
* Positive Phalen's test
* Persistent median artery within wrist region
* Bifid median nerve

Primary outcomes:
measure: Change in intraneural blood flow after intervention
timeFrame: Immediately prior to and after each intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: USC; Musculoskeletal Sonography & Occupational Performance Laboratory
state: California
city: Columbus
country: United States
facility: Ohio State University; School of Health and Rehabilitation Sciences
state: Ohio
Study officials:
affiliation: University of Southern California
name: Shawn C Roll, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02104154: Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting
Official title: Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Hepatic Disease
Lead sponsor: Samsung Electronics
Sponsor class: INDUSTRY
First posted: 2014-04-04
Enrollment: 32
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinics

Brief summary: To establish the performance characteristics of the Samsung LABGEO PT10 by comparing the test results of the PT10 Hepatic assay with results obtained from an FDA-cleared chemistry analyzer.

Detailed description: To establish the correlation between measurand values as obtained from the Samsung LABGEO PT10 Hepatic Panel at the point of care, and the corresponding measurand values as obtained on a commercial clinical chemistry analyzer, with respect to prospectively collected human serum specimens.

Eligibility criteria: Inclusion Criteria:

* Male or female subjects with a history of elevated liver enzymes or symptoms suggestive of elevated liver enzymes
* Presenting to the site and requiring testing for levels of liver enzymes as part of routine care at the site
* Subjects able and willing to provide written informed consent

Exclusion Criteria:

* Subjects unable or unwilling to provide written informed consent
* Subjects with a life-threatening disease or any serious, potentially life-threatening medical illness that may compromise patient safety or study conduct

Primary outcomes:
measure: Bias between Samsung LABGEO PT10 serum results and matching FDA-cleared comparator assay
timeFrame: baseline
Secondary outcomes:
measure: Mean percentage difference between all pairs of plasma and serum measurements using Bland-Altman plot of differences.
timeFrame: baseline
measure: Standard deviation and coefficients of variation of between run, between day and total precision.
timeFrame: 20 days
measure: Estimates of reference intervals by computing the 2.5th percentile of associated distribution of test measurement (for each analyte) and the 97.5th percentile of associated distribution.
timeFrame: baseline
measure: Mean percentage difference between all pairs of serum and whole blood measurements using Bland-Altman plot of differences.
timeFrame: baseline
measure: Mean percentage difference between all pairs of plasma and whole blood measurements using Bland-Altman plot of differences.
timeFrame: baseline
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
affiliation: Nexus DX
name: Nam Shin
role: STUDY_CHAIR
References:
Clinical trial NCT00844454: Multi-pronged Ethanol Ablation and Radiofrequency Ablation of Early-stage Hepatocellular Carcinoma
Official title: Ethanol Ablation Using a Multi-pronged Needle and Radiofrequency Ablation of Early-stage Hepatocellular Carcinoma: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatocellular Carcinoma
Keywords: hepatocellular carcinoma
PEI
RF ablation
tumor ablation
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2009-02-16
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the effectiveness of percutaneous ethanol ablation using a multi-pronged needle (QFEA) with that of percutaneous radiofrequency ablation (RFA) in the treatment of early-stage hepatocellular carcinoma (HCC).

Detailed description: Patients with early-stage (single tumor no more than 5 cm or up to 3 tumors each no more than 3 cm in size) primary hepatocellular carcinoma will be randomized into two percutaneous ablation treatment arms, including radiofrequency ablation and multi-pronged ethanol ablation. The local treatment responses, complications,and long-term disease-free survivals and overall survivals are analyzed.

Eligibility criteria: Inclusion Criteria:

* Primary hepatocellular carcinoma, single tumor ≤5 cm or up to 3 tumors each ≤3 cm
* Ultrasound detectable tumor
* Liver function classified as Child-Pugh A or B
* Platelet count \> 50,000/mm3, or prothrombin activity \> 50%
* Not suitable for resection or patient refused surgery

Exclusion Criteria:

* Vascular invasion and extrahepatic spread
* Patients allergic to ethanol

Primary outcomes:
measure: Local treatment responses
timeFrame: 2 years
Secondary outcomes:
measure: Disease-free survivals and overall survivals
timeFrame: 3 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: The First Affiliated Hospital of Sun Yat-Sen University
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: Mingde Lu, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06300554: 10th Mountain Healthy Minds Program App Study
Official title: 10th Mountain Healthy Minds Program App Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Well-Being, Psychological
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2024-03-08
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of the study is to evaluate the acceptability, feasibility, and preliminary effects of the Healthy Minds Program (HMP) App in approximately 150 active duty military members.

Detailed description: Participants will be informed about the study during regularly scheduled activities. They will be informed that enrolling in the study is voluntary.

Participants will complete a 10-15 minute battery of questionnaires at baseline and post-test. In between these assessments, they will be asked to download and use the Healthy Minds Program app for 4 weeks. Post-test assessment will occur following the 4-week intervention period.

Eligibility criteria: Inclusion Criteria:

* Active duty military at the 10th Mountain Division

Exclusion Criteria:

* N/A

Primary outcomes:
measure: System Usability Scale Score
timeFrame: post-test (up to 4 weeks)
measure: Acceptability of Intervention Measure (AIM)
timeFrame: post-test (up to 4 weeks)
measure: Intervention Appropriateness Measure (IAM)
timeFrame: post-test (up to 4 weeks)
measure: Feasibility of Intervention Measure (FIM)
timeFrame: post-test (up to 4 weeks)
measure: HMP App Usage: Did you use the Healthy Minds Program App (Yes or No)
timeFrame: post-test (up to 4 weeks)
measure: HMP App Usage: Did you download the Healthy Minds Program App (Yes or No)
timeFrame: post-test (up to 4 weeks)
Secondary outcomes:
measure: Change in Perceived Stress Score
timeFrame: baseline and post-test (up to 4 weeks)
measure: Change in WHO-5 Well-Being Score
timeFrame: baseline and post-test (up to 4 weeks)
measure: Change in PROMIS Depression Score
timeFrame: baseline and post-test (up to 4 weeks)
measure: Change in PROMIS Anxiety Score
timeFrame: baseline and post-test (up to 4 weeks)
measure: Change in Meaning of Life Questionnaire - Presence Subscale Score
timeFrame: baseline and post-test (up to 4 weeks)
measure: Change in NIH Toolbox Loneliness Score
timeFrame: baseline and post-test (up to 4 weeks)
measure: Change in Suicide Cognitions Scale Score
timeFrame: baseline and post-test (up to 4 weeks)
measure: HMP App Usage: How many times did you use the HMP App
timeFrame: post-test (up to 4 weeks)
Other outcomes:
measure: HMP App Usage: Reasons for not downloading the HMP App
timeFrame: post-test (up to 4 weeks)
measure: HMP App Usage: Reasons for not opening the HMP App
timeFrame: post-test (up to 4 weeks)
Locations:
city: Madison
country: United States
facility: University of Wisconsin
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Simon Goldberg, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00563654: Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
Official title: Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo on the Successful Rate of Trial Without Catheter in Patients With Acute Urinary Retention With Long Term Follow up
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Prostatic Hyperplasia
Urinary Retention
Acute Disease
Keywords: Benign Prostatic Hyperplasia (BPH)
Acute Retention of Urine (AUR)
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
First posted: 2007-11-26
Enrollment: 48
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare alfuzosin GITS once daily versus placebo in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.


Eligibility criteria: Inclusion Criteria:

* Aged 50 or above
* Admitted for AUR due to BPH with PVR of 500 ml or more

Exclusion Criteria:

* Previous history of TURP
* Use of alpha blockers within recent 8 months
* Renal impairment (serum creatinine \>140 umol/l)
* Poor premorbid state

Primary outcomes:
measure: Successful rate of Trial Without Catheter (TWOC) at phase 1
timeFrame: At discharge after TWOC (at the end phase one)
measure: Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1
timeFrame: From the end of phase one to eight months after successful TWOC (the end of phase 2)
Secondary outcomes:
measure: Proportion of subjects with hypotension or symptoms related to hypotension after administration of treatment drug for TWOC
timeFrame: From the time of treatment drug administration to the end of phase 1
measure: Peak flow rate (Qmax), voided volume (Vcomp) and post-voided residue volume (PVR)
timeFrame: At the end of phase I (discharge after TWOC) and at the end of phase 2
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: North District Hospital
Study officials:
affiliation: Department of Surgery, Division of Urology, North District Hospital
name: Chi Wai Cheng, Dr
role: PRINCIPAL_INVESTIGATOR
References: